Analyzing ASP Isotopes (NASDAQ:ASPI) and Daicel (OTCMKTS:DACHF)

Daicel (OTCMKTS:DACHF) and ASP Isotopes (NASDAQ:ASPI) are both materials companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares Daicel and ASP Isotopes”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daicel	N/A	N/A	N/A	$78.72	0.10
ASP Isotopes	$26.93 million	24.31	-$175.09 million	($1.32)	-3.23

Daicel has higher earnings, but lower revenue than ASP Isotopes. ASP Isotopes is trading at a lower price-to-earnings ratio than Daicel, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Daicel and ASP Isotopes, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daicel	0	1	0	0	2.00
ASP Isotopes	1	0	2	0	2.33

ASP Isotopes has a consensus price target of $13.00, indicating a potential upside of 204.45%. Given ASP Isotopes’ stronger consensus rating and higher possible upside, analysts clearly believe ASP Isotopes is more favorable than Daicel.

Profitability

This table compares Daicel and ASP Isotopes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daicel	N/A	N/A	N/A
ASP Isotopes	-644.40%	-112.46%	-53.36%

Institutional and Insider Ownership

18.6% of Daicel shares are held by institutional investors. Comparatively, 16.8% of ASP Isotopes shares are held by institutional investors. 14.4% of ASP Isotopes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Daicel beats ASP Isotopes on 6 of the 11 factors compared between the two stocks.

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, engineering plastics, and other businesses in Japan, China, and internationally. The company offers acetic acid, acetic acid derivative chemicals, acetate tow, acetic anhydride, thioglycolic acid, caprolactone derivatives, methyl 3-methoxyacrylate, cycloaliphatic epoxies, alkylamines comprising diethylhydroxyamine, and 1,3-butylene glycol, as well as cellulose acetate; and Actranza Lab, a drug delivery device. It also provides solutions for the electronics market, such as functional films and materials for use in smartphones, PCs, TVs, and in-vehicle displays; polymers and solvents for use in the semiconductor manufacturing process; optical lenses for use in VR, smartphones, and various sensors; printed electronic materials; and organic semiconductors. In addition, the company offers automobile airbags inflators comprising gas generation devices; pyro-fuses as safety systems for use in products, such as electric vehicles, renewable energy storage, and transmission systems and robots; and gas generators for seat belt pretensioners, as well as engineering plastics and plastic compound products, high performance polymer, functional sheets, formed trays, and packaging films. Further, it reuses water for medical care, drinking water, food, and wastewater fields; and provides chiral columns, chiral reagents, pharma excipients, bellocea S7, flavocell(S-equol), konjac ceramide, polyglycerols, urolithin A, and excipients for food, as well as analytical and separation services. The company’s products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.

About ASP Isotopes

ASP Isotopes Inc., a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.